Biopharmaceutical News and Research

RSS

New treatment protects mice from MERS infection

In a new study, University of Maryland School of Medicine researchers have had promising results with a new treatment for Middle East Respiratory Syndrome (MERS). The study, published today in the journal Science Translational Medicine, found a new treatment that protected mice from MERS infection.

18 Feb 2016

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it has received funding approval in the amount of €3 million from the German Federal Ministry of Education and Research for the so-called CancerMark project.

16 Feb 2016

Positive data on ability of MyoKardia’s MYK-461 to prevent development of HCM published in Science

MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the leading medical journal Science.

8 Feb 2016

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar.

3 Feb 2016

BioLineRx's BL-7010 confirmed as Class IIb medical device in European Union

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union.

25 Jan 2016

Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia Biopharmaceuticals, Inc., a biotechnology company, is catalyzing the development of first-in-class neurometabolic treatments for concussions and other aspects of brain injury.

21 Jan 2016

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer.

21 Jan 2016

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center has been awarded a 10-month, $4.6 million contract funded by the Department of Defense to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain.

21 Jan 2016

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015.

19 Jan 2016

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).

13 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has formed an exclusive partnership with the world-renowned Karolinska Institutet in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies.

11 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

Purified cannabinoid reduces seizures in children and young adults with treatment-resistant epilepsy

Children and young adults with severe forms of epilepsy that does not respond to standard antiepileptic drugs have fewer seizures when treated with purified cannabinoid, according to a multi-center study led by researchers from UCSF Benioff Children's Hospital San Francisco.

6 Jan 2016

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.

6 Jan 2016

FDA permits Sound Pharmaceuticals to start SPI-1005 clinical trial for treatment of Meniere's Disease

Sound Pharmaceuticals is pleased to announce that it began enrolling a clinical trial to test SPI-1005 in the treatment of Meniere's Disease (MD). MD or idiopathic endolymphatic hydrops is an inner ear disease that involves episodic vertigo, sensorineural hearing loss, and tinnitus.

5 Jan 2016

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers.

5 Jan 2016

CFDA issues new drug certificate and production license for Sinovac's EV71 vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration issued the new drug certificate and production license for its Enterovirus 71 ("EV71") vaccine.

4 Jan 2016

Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies.

4 Jan 2016

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

24 Dec 2015

Biopharmaceutical News and Research

New treatment protects mice from MERS infection

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

Positive data on ability of MyoKardia’s MYK-461 to prevent development of HCM published in Science

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

BioLineRx's BL-7010 confirmed as Class IIb medical device in European Union

Oxeia accelerating development of neurometabolic treatments for concussions

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

CASI Pharmaceuticals receives $10.3 million in strategic financing

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Purified cannabinoid reduces seizures in children and young adults with treatment-resistant epilepsy

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

FDA permits Sound Pharmaceuticals to start SPI-1005 clinical trial for treatment of Meniere's Disease

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

CFDA issues new drug certificate and production license for Sinovac's EV71 vaccine

Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News